GlobeNewswire by notified

Gunvor Secures US $1.39 Billion Revolving Credit Facility

Share

Gunvor Group Ltd / Gunvor Secures US $1.39 Billion Revolving Credit Facility . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Strong bank support for Group strategy results in substantial over-subscription

GENEVA, Nov. 16, 2017 (GLOBE NEWSWIRE) -- Gunvor Group Ltd ("Gunvor" or the "Group") has signed a US $1.39 billion Revolving Credit Facility ("RCF") in favour of Gunvor International B.V. and Gunvor SA (the "Borrowers"). The RCF, launched at US $1 billion, was substantially over-subscribed, drawing in US $1.81 billion, a record high for the facility. The RCF was scaled back to accommodate the needs of the Group, which will use the funds to finance general corporate purposes and working capital requirements.

"Gunvor continues to receive considerable support from both its existing banking partners as well as from new ones," said Jacques Erni, CFO, Gunvor Group. "Thanks to our continuous efforts to tighten cash management and improve financial structuring, we have become more efficient financially, with reduced working capital needs. At the same time, Gunvor continues to implement our strategy of geographic expansion and product diversification, generating positive returns in a challenging and evolving environment."

The RCF will replace the maturing Tranche A (US $1.415 billion) of the Borrowers' US $1.67 billion RCF dated 17 November 2016 and Tranche B (US $210 million) of the US $1.36 billion RCF dated 23 November 2015. The first RCF for Gunvor in Europe was launched in 2008 and is complemented by the Group's Asian Revolving Credit Facilities, Borrowing Base facilities, and OBSI Facility.

ABN AMRO Bank N.V., Credit Agricole Corporate and Investment Bank, Credit Suisse (Switzerland) Ltd, DBS Bank Ltd., ING Bank N.V., Natixis, Rabobank, Société Générale Corporate & Investment Banking, UBS Switzerland AG and UniCredit Bank AG (together the "Bookrunning Mandated Lead Arrangers") were mandated to arrange the Facility. ABN AMRO Bank N.V., Credit Agricole Corporate and Investment Bank, ING Bank N.V., Natixis and Rabobank acted as Active Bookrunners while Credit Suisse (Switzerland) Ltd is Facility and Swingline Agent.

Deutsche Bank AG, Amsterdam Branch, Mizuho Bank, Ltd, and Emirates NBD PJSC, London branch joined as Senior Mandated Lead Arrangers, with APICORP, Citigroup Global markets Limited, DZ Bank AG Deutsche Zentral-Genossenschaftsbank, Frank am Main, KfW-IPEX, Nedbank and Sumitomo Mitsui Trust Bank as Mandated Lead Arrangers.

The Bank of Tokyo-Mitsubishi UFJ, Limited, Commerzbank, Raiffeisen Bank International AG, and Sumitomo Mitsui Banking Corporation joined as Lead Arrangers, with Mashreqbank, Arab Bank (Switzerland) Ltd, Banco do Brasil, Bank ABC, Banque de Commerce et de Placements, Goldman Sachs, Gulf International Bank, Habib Bank AG Zurich, HSH Nordbank and UBAF as Arrangers, with Participants China Construction Bank, Beijing, Swiss Branch Zurich, Commercial Bank of Dubai, Garanti Bank International, Banque Cantonale de Genève, Attijariwafa Bank and Erste Bank AG.

The Facility consists of two tranches, available to Gunvor International B.V. and Gunvor SA:

  • Tranche A: US $1.14 billion 364-day revolving credit facility with two 364-day extension options, and;
  • Tranche B: US $250 million 3-year revolving credit facility with one 364-day extension option

About Gunvor Group
Gunvor Group is one of the world's largest independent commodities trading houses by turnover, creating logistics solutions that safely and efficiently move physical energy and bulk materials from where they are sourced and stored to where they are demanded most. With strategic investments in industrial infrastructure-refineries, pipelines, storage, terminals, mining and upstream-Gunvor further generates sustainable value across the global supply chain for its customers.

More information can be found at GunvorGroup.com or @Gunvor.

Contact
Mr. Seth Thomas Pietras
stp@gunvorgroup.com
+41 79 870 62




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Gunvor Group Ltd via Globenewswire

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update8.5.2024 22:15:38 CEST | Press release

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDACBased on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update. “At the upcoming 2024 ASCO meeting, we are looking forward to presenting multiple datasets including the first clinical data on safety and efficacy of petosemtamab in combination with pembrolizumab in previously untreated head and neck cancer. With p

CrossAmerica Partners LP Reports First Quarter 2024 Results8.5.2024 22:15:00 CEST | Press release

Allentown, PA, May 08, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports First Quarter 2024 Results Reported First Quarter 2024 Net Loss of $17.5 million that includes a $15.9 million loss on lease terminations with Applegreen, Adjusted EBITDA of $23.6 million and Distributable Cash Flow of $11.7 million compared to a Net Loss of $1.0 million, Adjusted EBITDA of $31.7 million and Distributable Cash Flow of $19.1 million for the First Quarter 2023Reported First Quarter 2024 Gross Profit for the Wholesale Segment of $27.0 million compared to $31.2 million of Gross Profit for the First Quarter 2023 and First Quarter 2024 Gross Profit for the Retail Segment of $54.4 million compared to $50.8 million of Gross Profit for the First Quarter 2023Leverage, as defined in the CAPL Credit Facility, was 4.49 times as of March 31, 2024, compared to 4.21 times as of December 31, 2023The Distribution Coverage Ratio for the trailing twelve months ended March 31, 2024 was 1.37 times compared to 1

Oculis Reports Q1 2024 Financial Results and Provides Company Updates8.5.2024 22:10:00 CEST | Press release

ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED); RELIEF topline results anticipated in Q2 2024Completed $59 million registered direct equity offering and concurrent listing on Nasdaq Iceland Main Market in April 2024, extending cash runway into the second half of 2026Strengthened executive leadership team and U.S. presence with the appointments of accomplished and seasoned professionals as President of Research & Development and Chief Human Resources Officer Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the three-month period ended March 31, 2024, and an overview of the Company’s progress. Riad Sherif M.D., Chief

Nokia Corporation: Repurchase of own shares on 08.05.20248.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 08 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 08.05.2024 Espoo, Finland – On 08 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,9483.49CEUX--BATE--AQEU--TQEX--Total362,9483.49 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Trading in GN Store Nord shares by board members, executives and associated persons8.5.2024 21:28:31 CEST | Press release

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associated Name Jørgen Bundgaard Hansen Reason for the notification Position/status Member of the Board of Directors Initial notification/Amendment Initial notification Details of the issuer Name GN Store Nord A/S LEI 5493008U3H3W0NKPFL10 Details of the transaction(s) Description of the financial instrument, type of instrument Identification code Shares DK0010272632 Nature of the transaction Purchase of shares Price(s) and volume(s) Price(s) DKK 201.0 DKK 201.1 DKK 201.1 DKK 201.0 DKK 201.0 DKK 201.0 DKK 201.1 DKK 201.1 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.0 DKK 201.3 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.3 DKK 201.5 DKK

HiddenA line styled icon from Orion Icon Library.Eye